IP Library › Granted Patent US 9,101,621
Granted Patent B2
US 9,101,621 · App. 14/255,211 · Granted Aug 11, 2015

Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation

Inventor: Jerome B. Zeldis (Princeton, NJ)
Assignee: Celgene Corporation
A61K31/454A61K31/00A61K31/198A61K31/40A61K31/4035A61K31/425A61K31/445A61K31/4439A61K31/475A61K31/515A61K31/573A61K31/675A61K31/704A61K31/7048A61K35/12A61K39/0011A61K39/3955A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,101,621
App. No.
14/255,211
Granted
Aug 11, 2015
Kind
B2
Abstract

Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Claims (22)

1. A method of treating multiple myeloma, which comprises administering to a patient having multiple myeloma about 1 to about 50 mg per day of a compound having the formula:

or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein the patient has previously received stem cell transplantation.

2. The method of claim 1 , wherein the multiple myeloma is relapsed, refractory, or relapsed and refractory multiple myeloma.

3. The method of claim 1 , wherein the compound is administered for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle.

4. The method of claim 1 , wherein the compound is administered every day.

5. The method of claim 1 , wherein the compound is administered orally.

6. The method of claim 1 , wherein the compound is administered in the form of a capsule or tablet.

7. The method of claim 1 , wherein the compound is administered in a capsule of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg.

8. The method of claim 6 , wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

9. The method of claim 1 , wherein the compound is administered in an amount of about 25 mg per day.

10. The method of claim 1 , wherein the compound is administered in an amount of about 15 mg per day.

11. The method of claim 1 , wherein the compound is administered in an amount of about 10 mg per day.

12. The method of claim 1 , wherein the compound is administered in an amount of about 5 mg per day.

13. The method of claim 3 , wherein the compound is administered in an amount of about 25 mg per day.

14. The method of claim 4 , wherein the compound is administered in an amount of about 5 mg, 10 mg or 15 mg per day.

15. The method of claim 1 , wherein the stem cell transplantation is autologous stem cell transplantation.

16. The method of claim 1 , wherein the stem cell transplantation is hematopoietic stem cell transplantation.

17. The method of claim 1 , wherein the stem cell transplantation is peripheral blood stem cell transplantation.

18. The method of claim 1 , wherein the compound is administered in an amount of about 2.5 mg per day.

19. The method of claim 3 , wherein the compound is administered in an amount of about 10 mg per day.

20. The method of claim 1 , wherein the compound is administered in an amount of about 20 mg per day.

21. The method of claim 1 , wherein the compound is administered in a capsule containing from about 1 to about 50 mg of the compound.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2014
From: ZELDIS, JEROME B.
To: CELGENE CORPORATION
Reel/Frame 032698/0817 →
Continuity (8)
Continuation 14201069 · Mar 7, 2014
Continuation 13782728 · Mar 1, 2013
Continuation 13488888 · Jun 5, 2012
Continuation 12640702 · Dec 17, 2009
Continuation 10438213 · May 15, 2003
Provisional Application 60380842 · May 17, 2002
Provisional Application 60424600 · Nov 6, 2002
Related Publication 20140308344A1 · Oct 16, 2014